Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Methicillin-Resistant Staphylococcus Aureus

Conditions

Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections

Trial Timeline

Mar 30, 2017 → Jan 1, 2024

NCT ID

NCT02814916

About Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin

Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin is a phase 3 stage product being developed by AbbVie for Methicillin-Resistant Staphylococcus Aureus. The current trial status is completed. This product is registered under clinical trial identifier NCT02814916. Target conditions include Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections.

What happened to similar drugs?

1 of 1 similar drugs in Methicillin-Resistant Staphylococcus Aureus were approved

Approved (1) Terminated (0) Active (0)

✅Imipenem/cilastatinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02814916	Phase 3	Completed	Mar 30, 2017	Jan 1, 2024	Methicillin-Resistant Staphylococcus Aureus

Competing Products

2 competing products in Methicillin-Resistant Staphylococcus Aureus

See all competitors

Product	Company	Stage	Hype Score
Imipenem/cilastatin	Pfizer	Approved	39
Linezolid + Vancomycin	Pfizer	Pre-clinical	26